You are here

Zejula

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks

BioSpace

Gilead Sciences

Flag link:

GSK told to pay higher royalties to AZ on Zejula sales

GSK told to pay higher royalties to AZ on Zejula sales

Pharmaphorum

Flag link:

GSK’s “crown jewels” already look tarnished

GSK’s “crown jewels” already look tarnished

EP Vantage

Flag link:

GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request

GSK Restricts the Use of PARP Inhibitor in Ovarian Cancer at the FDA's Request

BioSpace

PARP inhibitors

Flag link:

GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial

GSK’s Zejula offers lasting PFS benefit in Phase III ovarian cancer trial

Clinical Trials Arena

clinical trials

Flag link:

ASCO-GU – prostate cancer PARPS move to the front line

ASCO-GU – prostate cancer PARPS move to the front line

EP Vantage

prostate cancer

PARP inhibitors

Clovis Oncology

Flag link:

AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report

AstraZeneca takes PARP battle to court, seeking a larger claim to GSK's key cancer med Zejula: report

Fierce Pharma

Flag link:

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

With FDA decision looming, GSK sweetens the PD-1 pot for discovery partner AnaptysBio as Hal Barron moves to guard his oncology strategy

Endpoints

Flag link:

GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track

GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track

Xconomy

belantamab mafodotin

immuno-oncology

Flag link:

GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations

GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations

Endpoints

Flag link:

FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer

FDA Accepts GSK's sNDA for Zejula as a First-Line Maintenance Treatment in Ovarian Cancer

BioSpace

Flag link:

GSK’s CEO Walmsley aiming for six new approvals in 2020

GSK’s CEO Walmsley aiming for six new approvals in 2020

Pharmaforum

belantamab mafodotin

Flag link:

AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

AZ and Merck, racing against Glaxo, nab Lynparza 'priority' boost in ovarian cancer

Fierce Pharma

priority review

Flag link:

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

GlaxoSmithKline celebrates another Zejula win in late-line ovarian cancer — and an FDA nod for the HRD biomarker

Endpoints

PARP inhibitors

Flag link:

GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

GSK’s niraparib meets PFS goal in phase 3 PRIMA trial

Pharmaceutical Business Review

clinicial trials

advanced ovarian cancer

Flag link:

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

Separate GSK, AstraZeneca trial results may widen ovarian cancer drug use

Yahoo/Reuters

ovarianc cancer

PARP inhibitors

Flag link:

GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO

GSK and AstraZeneca's PARP Inhibitors Will Flex Their Muscles at ESMO

BioSpace

PARP inhibitors

Flag link:

ESMO 2019 preview – PARPs on parade

ESMO 2019 preview – PARPs on parade

EP Vantage

PARP inhibitors

Flag link:

GSK drug helps ovarian cancer patients live longer in late-stage study

GSK drug helps ovarian cancer patients live longer in late-stage study

Yahoo/Reuters

clinical trials

Flag link:

GSK wins speedy FDA Zejula review in ovarian cancer niche

GSK wins speedy FDA Zejula review in ovarian cancer niche

Fierce Pharma

late-stage ovarian cancer

Flag link:

Pages